APVO
Aptevo Therapeutics Inc.
Key Financials
Revenue
$3.1M
0.0%
Operating Income
$-26312000
↓ 7.0%
Net Income
$-25967000
↓ 7.6%
EPS (Diluted)
$-87.27
↑ 0.1%
Total Assets
$27.2M
↑ 74.4%
Cash & Equivalents
$21.6M
↑ 148.1%
Total Liabilities
$9.8M
↓ 9.4%
Shareholders' Equity
$17.4M
↑ 265.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-K | 3/26/2026 | View on SEC |
| 8-K | 3/26/2026 | View on SEC |
| 8-K | 3/11/2026 | View on SEC |
| 8-K | 2/19/2026 | View on SEC |
| SCHEDULE 13G/A | 2/17/2026 | View on SEC |
| SCHEDULE 13G/A | 2/17/2026 | View on SEC |
| 8-K | 2/3/2026 | View on SEC |
| EFFECT | 1/30/2026 | View on SEC |
| 424B4 | 1/30/2026 | View on SEC |
| S-1 | 1/28/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | APVO |
| Company Name | Aptevo Therapeutics Inc. |
| CIK | 1671584 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 206-838-0500 |